Capricor Therapeutics (NASDAQ:CAPR) Shares Gap Up – Should You Buy?

Shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR) gapped up prior to trading on Monday . The stock had previously closed at $27.90, but opened at $30.77. Capricor Therapeutics shares last traded at $30.04, with a volume of 932,894 shares changing hands.

Key Capricor Therapeutics News

Here are the key news stories impacting Capricor Therapeutics this week:

• Positive Sentiment: FDA resumed review of the Biologics License Application for Deramiocel and lifted the prior Complete Response Letter; the resubmission is classified as a Class 2 with a PDUFA target action date of August 22, 2026 — a clear regulatory catalyst toward potential approval. Article Title
• Positive Sentiment: HC Wainwright reiterated a Buy rating and set a $60 price target (implying substantial upside from current levels), which can support investor confidence and buying interest. Article Title
• Neutral Sentiment: Capricor will report Q4 and full-year 2025 results and provide a corporate update on March 12 — this is a near-term event that could add volatility depending on financials and program updates. Article Title
• Neutral Sentiment: News that the FDA CBER head (Dr. Vinay Prasad) is leaving in April introduces some regulatory leadership change risk/uncertainty for biotech review dynamics, but the direct impact on CAPR’s review timeline is unclear. Article Title
• Neutral Sentiment: Reported large short-interest “increase” items show zero shares and NaN changes — this appears to be a data anomaly and is unlikely to be a meaningful driver unless later confirmed by accurate short-interest filings.

Analysts Set New Price Targets

A number of brokerages recently commented on CAPR. Cantor Fitzgerald reiterated an “overweight” rating on shares of Capricor Therapeutics in a report on Wednesday, January 14th. Maxim Group raised their target price on Capricor Therapeutics from $25.00 to $50.00 and gave the company a “buy” rating in a research report on Thursday, December 4th. Piper Sandler reiterated an “overweight” rating and set a $45.00 target price (up from $20.00) on shares of Capricor Therapeutics in a research note on Wednesday, December 10th. B. Riley Financial reissued a “buy” rating and issued a $50.00 price target (up from $21.00) on shares of Capricor Therapeutics in a report on Monday, December 15th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Capricor Therapeutics in a research report on Monday, December 29th. Nine analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $40.82.

Capricor Therapeutics Price Performance

The firm has a fifty day simple moving average of $25.47 and a two-hundred day simple moving average of $16.11. The firm has a market capitalization of $1.85 billion, a P/E ratio of -18.56 and a beta of 0.37.

Institutional Investors Weigh In On Capricor Therapeutics

Several large investors have recently added to or reduced their stakes in CAPR. Goldman Sachs Group Inc. lifted its holdings in Capricor Therapeutics by 39.5% during the first quarter. Goldman Sachs Group Inc. now owns 411,141 shares of the biotechnology company’s stock valued at $3,902,000 after purchasing an additional 116,373 shares during the last quarter. Ellerson Group Inc. ADV purchased a new position in shares of Capricor Therapeutics in the second quarter worth about $170,000. Simplify Asset Management Inc. bought a new stake in shares of Capricor Therapeutics in the second quarter valued at approximately $397,000. Geode Capital Management LLC raised its position in shares of Capricor Therapeutics by 6.8% in the second quarter. Geode Capital Management LLC now owns 963,080 shares of the biotechnology company’s stock valued at $9,565,000 after purchasing an additional 61,701 shares during the period. Finally, Citizens Financial Group Inc. RI lifted its stake in shares of Capricor Therapeutics by 249.2% during the 2nd quarter. Citizens Financial Group Inc. RI now owns 35,000 shares of the biotechnology company’s stock valued at $348,000 after buying an additional 24,977 shares in the last quarter. Hedge funds and other institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.